27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Moleculin Biotech Inc (NASDAQ:MBRX)'s stock was advancing Wednesday on heavy volume.
Moleculin, which focuses on drugs targeting highly resistant tumors, said it has filed new patents covering the production and reconstitution of annamycin, its investigational drug for relapsed or refractory acute myeloid leukemia.
Annamycin is is being evaluated in two Phase 1/2 trials. The investigation drug has an Orphan Drug Designation as well as Fast Track Designation from the FDA.
The company said if the new patent applications are approved, they would create 20 years of protection for the asset.
"Since we have recently announced promising preclinical data showing the potential for Annamycin to become an important treatment for lung metastases, having this broad coverage should add considerable value to this asset," CEO Walter Klemp said in a statement.
Moleculin shares were trading higher by 6.03% at $1.23 at the time of publication Wednesday.
Related Links:
Why CorMedix Shares Are Rallying
Aclaris Shares Trade Higher On Patent Win For Facial Redness Drug
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!